Mega features in Forbes Asia’s Best Under A Billion 2023 list for third consecutive year

This year’s annual Best Under A Billion list recognizes 200 small and midsized publicly traded companies in the region that outperformed despite stiff global headwinds like inflation and rising funding costs. See the full list, sorted alphabetically, here .

This year’s list includes 58 returnees from the previous year, reflecting their resiliency in a fast-changing environment, Mega Lifesciences being one amongst them, which has made Best Under A Billion for a third consecutive year.

ABOUT MEGA LIFESCIENCES

Mega Lifesciences manufactures, markets and distributes medications and nutritional supplements. The company has manufacturing facilities in Australia, Thailand and Indonesia. It was founded in 1982 and is headquartered in Bangkok.

METHODOLOGY

The companies on the list, were selected based on a composite score that incorporated their overall track record in measures such as debt, sales and earnings-per-share growth over both the most recent fiscal one-and three-year periods, and the strongest one-and five-year average returns on equity.

Aside from quantitative criteria, qualitative screens were used as well, such as excluding companies with serious governance issues, questionable accounting, environmental concerns, management issues or legal troubles